Non-Hodgkin Lymphoma News

Non-Hodgkin Lymphoma - Videos

STOP! You must read this information before you decide about your cancer treatment. Over 350 non-toxic natural and alternative treatments that have helped thousands of people beat their cancer. Over 2,000 testimonials! Success rates for surgery, chemo and radiation revealed! Free information on financial and other help available. Download this set of 4 e-Books and Reports NOW. It could save your life.

The set of e-books and reports at www.naturalcancertreatments.com gives you EVERYTHING you need to know about natural and alternative treatments for cancer.

Non-Hodgkin’s Lymphoma - News

Non-Hodgkin’s Lymphoma News

Non-Hodgkins Lymphoma - Google News
©2009 Google
Google News

Lack of Evidence Hinders Cancer Treatment in Elderly - Wall Street Journal

Lack of Evidence Hinders Cancer Treatment in Elderly Wall Street Journal Consider the case of a patient I'll call Ted, an 83-year-old man I treated two years ago for non-Hodgkin's lymphoma, an often-curable form of cancer. ... The Need for New Research to Include Old PatientsWall Street Journal Blogs all 2 news articles »

Broadway World

Impressionist Fred Travalena dead at 66 The Star-Ledger - NJ.com Fred Travalena, the impressionist known as "The Man of a 1000 Faces," died Sunday of a recurrence of an aggressive form of Non-Hodgkin's lymphoma, ... Impressionist Fred Travalena Dies at 66Associated Content Fred Travalena dies at 66; master impressionist and singerLos Angeles Times Fred Travalena (Los Angeles Times File Photo)Newsday FOXNews -About - News & Issues -E! Online -Post Chronicle all 262 news articles »

Flaws in the Case Against BPA New York Times Cisplatin (Platinol) is also used to treat testicular, ovarian and bladder cancers as well as Hodgkins and non Hodgkins lymphomas. ... and more »

Biotech Stock Mailbag: Spectrum TheStreet.com ... decision tonight on a label expansion for Zevalin that should allow the drug to be used by a much larger number of patients with non-Hodgkin's lymphoma. ... Institutional Investors Buy $21 Million Of Spectrum Stock On Eve ...OfficialWire Afternoon Report - CTIC - Biotech Stock Mailbag: SpectrumTransWorldNews (press release) Spectrum Pharmaceuticals to Benefit from FDA Action on Zevalin? 0 ...Seeking Alpha all 43 news articles »

Improving Survival From Non-Hodgkin's Lymphoma AIDSmeds.com HIV/AIDS Treatment News Survival among people with HIV who are diagnosed with non-Hodgkin's lymphoma (NHL) continues to improve, according to an encouraging reported published ... and more »

5 Cold Stocks Heating Up Motley Fool Spectrum's non-Hodgkin's lymphoma treatment Zevalin is before the FDA, as the company awaits a decision on whether to expand its non-Hodgkin's lymphoma ... and more »

Metro

Twelve year study suggests that vegetarians have a lower cancer ... Examiner.com Vegetarians are less likely than meat eaters to develop bladder cancer, stomach cancer, non-Hodgkin's lymphoma and multiple myeloma. ... Vegetarianism linked to lower cancer riskMinnPost.com Vegetarians develop 'fewer' cancersTimes of India Vegetarians 'have lower cancer risk'Special Broadcasting Service UK Express all 196 news articles »

Good survival for HIV patients diagnosed with non-Hodgkin's lymphoma Aidsmap Two-thirds of HIV-positive individuals with non-Hodgkin's lymphoma are alive a year after its diagnosis, European investigators report in a study published ... and more »

Stem Cell Possibilities Energize the Market Genetic Engineering News (press release) ... osteoporosis, Crohn's disease, diabetes, Parkinson's disease, Alzheimer's disease, and cancers such as multiple myeloma and non-Hodgkin's lymphoma. ... and more »

Benefit Sunday for Fairbury woman facing stem cell transplant for ... Pontiac Daily Leader A benefit will be held at Gig's Place in Fairbury on Sunday at 1 pm to aide a woman's battle with Stage 4 non-hodgkins lymphoma. April Sedam, of Fairbury, ... and more »

The Leukemia & Lymphoma Society's LymphomaCAST
Podcast for those living with Hodgkin and non-Hodgkin lymphoma. Sponsored by The Leukemia & Lymphoma Society

Emerging Therapies in Leukemia, Lymphoma & Myeloma
Emerging Therapies in Leukemia, Lymphoma & Myeloma June 16, 2009 This program featured Gail J. Roboz, MD, Associate Professor of Medicine, Director, Leukemia Program, Weill Medical College of Cornell University/New York-Presbyterian Hospital, New York, NY and John P. Leonard, MD, Richard T. Silver Distinguished Professor of Hematology and Medical Oncology, Professor of Medicine, Weill Medical College of Cornell University/New York-Presbyterian Hospital, Clinical Director, New York - Cornell Center for Lymphoma and Myeloma, New York, NY and Robert Z. Orlowski, MD, PhD, Director, Myeloma Section, Associate Professor, Departments of Lymphoma/Myeloma and Experimental Therapeutics, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX. This program was supported in part by Celgene.
News on NHL from the ASH Annual Meeting - Part 2
12/18/2008 - Part 2 (Q&A) News on NHL from the American Society of Hematology (ASH) Annual Meeting This program featured Bruce D. Cheson, MD, FACP, Professor of Medicine, Head of Hematology, Director, Hematology Research, Lombardi Cancer Center, Georgetown University Hospital, Washington, DC. This program was sponsored by The Leukemia & Lymphoma Society and was supported by an educational grant from Genentech BioOncology and Biogen Idec.
News on NHL from the ASH Annual Meeting - Part 1
12/18/2008 - Part 1 (Presentation) News on NHL from the American Society of Hematology (ASH) Annual Meeting This program featured Bruce D. Cheson, MD, FACP, Professor of Medicine, Head of Hematology, Director, Hematology Research, Lombardi Cancer Center, Georgetown University Hospital, Washington, DC. This program was sponsored by The Leukemia & Lymphoma Society and was supported by an educational grant from Genentech BioOncology and Biogen Idec.
Childhood Leukemia and Lymphoma: An Update
Childhood Leukemia and Lymphoma: An Update on Current and Emerging Therapies This program featured Sima Jeha, M.D., Director, Leukemia/Lymphoma Developmental Therapeutics, Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN. This program was sponsored by The Leukemia & Lymphoma Society and was supported by a grant from The Jeff Gordon Foundation.
NHL: Current Treatments and Emerging Therapies - Part 2
NHL: Current Treatments and Emerging Therapies September 8, 2008 - Part 2 (Q&A) This program featured Andrew D. Zelenetz, M.D., Ph.D., Chief, Lymphoma Service, Division of Hematology/Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY. This program was sponsored by The Leukemia & Lymphoma Society, and was supported by an unrestricted educational grant from Genentech BioOncology and Biogen Idec. For related information go to http://www.leukemia-lymphoma.org/all_page?item_id=492628
NHL: Current Treatments and Emerging Therapies - Part 1
NHL: Current Treatments and Emerging Therapies September 8, 2008 - Part 1 (Presentation) This program featured Andrew D. Zelenetz, M.D., Ph.D., Chief, Lymphoma Service, Division of Hematology/Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY. This program was sponsored by The Leukemia & Lymphoma Society, and was supported by an unrestricted educational grant from Genentech BioOncology and Biogen Idec. For related information go to http://www.leukemia-lymphoma.org/all_page?item_id=492628
Childhood Cancer Survivorship: The Family's Journey Forward
5/29/2008 This program featured Nancy F. Cincotta, M.S.W., L.C.S.W., A.C.S.W., B.C.D., psychosocial director, Camp Sunshine, Casco, ME. This program was sponsored by The Leukemia & Lymphoma Society.
Progress in NHL Treatment, Part 2
5/20/2008, Part 2 This program on non-Hodgkin lymphoma (NHL) featured John W. Sweetenham, M.D., professor of medicine, director of clinical research, Taussig Cancer Institute, Cleveland Clinic, Ohio. This program was sponsored by The Leukemia & Lymphoma Society. In collaboration with Abrale.
Progress in NHL Treatment, Part 1
5/20/2008, Part 1 This program on non-Hodgkin lymphoma (NHL) featured John W. Sweetenham, M.D., professor of medicine, director of clinical research, Taussig Cancer Institute, Cleveland Clinic, Ohio. This program was sponsored by The Leukemia & Lymphoma Society. In collaboration with Abrale.
Progress in Mantle Cell Lymphoma: Update from the Experts 2
4/30/2008 - Part 2 This program featured John P. Leonard, MD, The Richard T. Silver Distinguished Professor of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY and Brad S. Kahl, MD, Associate Professor of Medicine, Director, Lymphoma Service, University of Wisconsin School of Medicine and Public Health, Madison, WI. This program was sponsored by The Leukemia & Lymphoma Society and supported by Celgene and Millennium Pharmaceuticals.
Progress in Mantle Cell Lymphoma: Update from the Experts 1
4/30/2008 - Part 1 This program featured John P. Leonard, MD, The Richard T. Silver Distinguished Professor of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY and Brad S. Kahl, MD, Associate Professor of Medicine, Director, Lymphoma Service, University of Wisconsin School of Medicine and Public Health, Madison, WI. This program was sponsored by The Leukemia & Lymphoma Society and supported by Celgene and Millennium Pharmaceuticals.
Stem Cell Transplantation: Current Trends/Future Directions
2/21/2008 This program featured Armand Keating, MD, FRCP(C), Professor of Medicine, Director, Division of Hematology, Epstein Chair in Cell Therapy and Transplantation at the University of Toronto. Director, Cell Therapy Program at Princess Margaret Hospital/Ontario Cancer Institute in Toronto, Ontario, Canada. This program was sponsored by The Leukemia and Lymphoma Society. Click here for the direct link to the audio: http://lls.hipcast.com/deluge/c940160b-5502-04f4-cb52-949b96782aaf.mp3
Sexuality and Intimacy After Cancer
3/11/2008 This program featured Sage Bolte, MSW, LCSW, OSW-C, Oncology Counselor, Breast Cancer Program, Life with Cancer® Inova Cancer Services in Fairfax, Virginia. This program was supported by The Leukemia and Lymphoma Society. Alternate link to the audio: http://lls.hipcast.com/deluge/c8641f38-69d9-13d3-34c8-663ded82ead0.mp3
Practical Tips for Managing Your Finances and Insurance 2
11/28/07 This program featured Beth Darnley, chief program officer, Patient Advocate Foundation, Newport News, Virginia and Anita Welborn, LMSW, director, Information Resource Center (IRC), The Leukemia & Lymphoma Society, White Plains, NY. This program was sponsored by The Leukemia & Lymphoma Society. Alternate link to the audio: http://lls.hipcast.com/download/ad858520-9141-1dc0-83f9-d88f41c26ae8.mp3
Advocating For Your Child's Learning Needs
2/13/08 Advocating For Your Child's Learning Needs: Through Treatment and Beyond This program featured Daniel Armstrong, PhD, professor & associate chair, Department of Pediatrics, director, Mailman Center for Child Development, associate chief of staff, Holtz Children's Hospital at the University of Miami, Jackson Memorial Medical Center, director, University of Miami Sickle Cell Center, Miami, Florida. This program was part of our Focus on Childhood Cancers Educational Series and was sponsored by The Leukemia and Lymphoma Society. Alternate link to the audio: http://lls.hipcast.com/deluge/ceab5a99-d0bd-9b91-fe70-bcf68ea5001c.mp3
Practical Tips for Managing Your Finances and Insurance 1
11/28/07 Cancer Survivorship: Practical Tips for Managing Your Financial and Insurance Issues - Part 1 of 2 This program featured Beth Darnley, chief program officer, Patient Advocate Foundation, Newport News, Virginia and Anita Welborn, LMSW, director, Information Resource Center (IRC), The Leukemia & Lymphoma Society, White Plains, NY. This program was sponsored by The Leukemia & Lymphoma Society. Alternate link to the audio: http://lls.hipcast.com/download/2b62f7e8-7e73-ab61-88c1-70c8794e4aca.mp3
Spotlight on New Discoveries in NHL Part 2
12/12/2007 Update from the American Society of Hematoloty (ASH) Annual Meeting This program featured Wyndham Wilson, M.D., Ph.D, senior investigator, head, Lymphoma Therapeutics Section, National Cancer Institute, Bethesda, MD. Alternate link to the audio: http://lls.hipcast.com/deluge/c191974d-8461-640b-c8af-0f769e8a66da.mp3
Spotlight on New Discoveries in NHL Part 1
12/12/07 This program featured Wyndham Wilson, M.D., Ph.D, senior investigator, head, Lymphoma Therapeutics Section, National Cancer Institute, Bethesda, MD. Alternate link to the audio: http://lls.hipcast.com/download/ad3aff9d-08f4-d7ef-9da2-27a89d2385c2.mp3
Non-Hodgkin Lymphoma Treatment Advances
09/12/07 This program featured Jonathan W. Friedberg, MD, MMSc, Associate Professor of Medicine, Director, Inpatient Hematology Service, Director, Hematological Malignancies Clinical Research, University of Rochester, Wilmot Cancer Center, Rochester, NY. Alternate link to the audio: http://lls.hipcast.com/download/60b8cf7f-6a7c-0ecb-f9fd-4ed43b48ffbc.mp3
Lymphoma: Understanding the Role of Targeted Therapies
02/28/07 Lymphoma: Understanding the Role of Targeted Therapies This program featured John P. Leonard, M.D., associate professor of medicine, Weill Medical College of Cornell University, clinical director, Cornell Center for Lymphoma and Myeloma in New York, NY. This program was supported by an unrestricted educational grant from GlaxoSmithKline Oncology & Acute Care. Alternate link to the audio: http://lls.hipcast.com/download/fce0cae2-4e15-aed3-2b68-bb64a7cff978.mp3
Non-Hodgkin Lymphoma (NHL): From Diagnosis to Therapy
05/15/07 This program featured Andrew D. Zelenetz, M.D., chief, Lymphoma Service, Division of Hematology/Oncology, Department of Medicine at Memorial Sloan-Kettering Cancer Center. Alternate link to the audio: http://lls.hipcast.com/download/d3ce00b2-529a-c300-997e-35a89d8c2a9d.mp3
Hodgkin Lymphoma Update: Making Treatment Decisions
05/29/07 This program featured Mary K. Gospodarowicz, MD, FRCPC, FRCR (Hon.) medical director, Cancer Program, chief, Radiation Medicine Program at Princess Margaret Hospital, University Health Network, professor and chair, Department of Radiation Oncology at the University of Toronto, Ontario, Canada. Alternate link to the audio: http://lls.hipcast.com/download/4487b6f0-d09d-a571-05e8-96e76ae06213.mp3

Cancercompass News: hematological cancer
@copy; Copyright 2009, International Capital & Management Company, LLLP. All Rights Reserved.
CancerCompass is an online community committed to offering people living with cancer a place to receive cancer information and news, share knowledge, and share cancer treatment experiences. To learn more, visit our site today.

UPCI Joins ExCell Research Study Using Stem Cells For Leukemia And Lymphoma Patients
PITTSBURGH, Pennsylvania, and JERUSALEM, Israel -- The University of Pittsburgh Cancer Institute (UPCI) and the Gamida Cell - Teva Joint Venture announced today that the Institute has joined an elite group of cancer centers in Europe, the United States and Israel that are now enrolling patients to participate in the ExCell research study. The phase III study is assessing the safety and efficacy of StemEx(R), an investigational product derived from stem cells, as an alternative treatment to bone marrow transplants for hematological malignancies, including leukemia and lymphoma. StemEx is a graft of expanded stem/progenitor cells taken from a single unit of umbilical cord blood and then transplanted in combination with non-...
Individuals Who Apply Pesticides Are Found To Have Double The Risk Of Blood Disorder
WASHINGTON -- A study involving 678 individuals who apply pesticides, culled from a U.S. Agricultural Health Study of over 50,000 farmers, recently found that exposure to certain pesticides doubles one's risk of developing an abnormal blood condition called MGUS (monoclonal gammopathy of undetermined significance) compared with individuals in the general population. The disorder, characterized by an abnormal level of a plasma protein, requires lifelong monitoring as it is a pre-cancerous condition that can lead to multiple myeloma, a painful cancer of the plasma cells in the bone marrow. The study will appear in the June 18 issue of Blood, the official journal of the American Society of Hematology. "Previously, inconclu...
LSU Health Sciences Center Research Finds Single Gene Controls Growth Of Some Cancers
NEW ORLEANS -- Research led by Ashok Aiyar, PhD, Associate Professor of Microbiology at LSU Health Sciences Center New Orleans, showing that a single gene can control growth in cancers related to the Epstein-Barr virus and that existing therapeutics can inactivate it, will be published in the June 12, 2009 online issue of PLoS Pathogens. The Epstein-Barr virus (EBV) is closely associated with many human cancers such as Burkitt's lymphoma, Hodgkin's lymphoma, AIDS-related lymphomas, post-transplant lymphoproliferative disease, cancers of the nose and throat, and stomach cancer. In many of these malignancies, proteins made by EBV are necessary for tumor cells to grow indiscriminately. This is especially true of AIDS-relat...
ChemGenex's Omacetaxine May Provide First Viable Treatment Option For Highly Resistant Form Of CML
MELBOURNE, Australia, and MENLO PARK, California -- ChemGenex Pharmaceuticals Limited (ChemGenex) announced that the latest data from its pivotal study of omacetaxine in patients with T315I-positive chronic myeloid leukemia (CML) was the subject of an oral presentation and discussion today at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida. The open label Phase 2/3 study (CGX-635-CML-202) investigated the use of omacetaxine, administered subcutaneously in CML patients who had failed imatinib and who have the highly drug resistant T315I kinase domain mutation. Dr. Jorge Cortes, MD, Professor of Medicine and Deputy Chair in the Department of Leukemia at The University of Texas, MD Anderson Cancer Ce...
Dana-Farber Cancer Institute Presents Results Of Glycomimetics Lead Drug Candidate In Models Of Multiple Myeloma At American Society Of Clinical Oncology Annual Meeting
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of small molecule, glycobiology-based therapies for a broad range of indications announced that data from in vitro and in vivo preclinical studies of GMI-1070 in models of multiple myeloma will be presented at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO). The data suggest that selectin expression plays a key role in blood cancer cell homing to bone marrow, and that GlycoMimetics lead drug candidate pan-selectin inhibitor GMI-1070 reduces the rate at which multiple myeloma cells extravasate from the bloodstream, thereby inhibiting homing to the bone marrow. The new data suggests that there may be a basis for testing...
Afinitor Phase II Data Show Positive Results For Patients With Multiple Types Of Lymphoma, Leading To Phase III Trial
EAST HANOVER, N.J. -- New data show that Afinitor(R) (everolimus) tablets significantly shrunk tumors in 33% of patients with relapsed non-Hodgkin's lymphoma (NHL) and Hodgkin's disease(1). Based on results from this study and other early-stage research, Novartis has initiated a Phase III trial in the most common NHL, diffuse large B-cell lymphoma (DLBCL). Non-Hodgkin's lymphoma and Hodgkin's disease, also known as Hodgkin's lymphoma, refer to a variety of cancers affecting the immune system, such as DLBCL, mantle cell lymphoma and follicular lymphoma(2). Up to 60% of patients with aggressive types of NHL, including DLBCL, may be cured with appropriate therapy(3). However, NHL patients have a high risk of relapse after in...
Chemgenex's Omacetaxine Kills Leukemic Stem Cells In Human CML Models
MELBOURNE, Australia & MENLO PARK, Calif. -- ChemGenex Pharmaceuticals Limited, announced today that the results of pre-clinical research that demonstrated that omacetaxine kills model human leukemic stem cells were presented at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany on Sunday. Human leukemic stem cells are known to be insensitive to tyrosine kinase inhibitors (TKIs), the drug family currently approved to treat Chronic Myeloid Leukemia (CML). The work was carried out in collaboration with Professor Tessa Holyoake at the University of Glasgow, Scotland, UK. Ms. Elaine Allan, Clinical Scientist of the Scottish National Blood Transfusion Service working at the Paul O'Gorman Leukae...
Algeta Demonstrates Potential Of Alpha-Emitter Platform To Generate New Antibody Therapeutics Targeting Breast Cancer And Lymphoma
Oslo, Norway -- Algeta ASA, the cancer therapeutics company, announces that a series of scientific papers demonstrating the targeted and localized anticancer potential of the alpha-emitter thorium-227 (227Th) linked to trastuzumab (Herceptin) and to rituximab (Rituxan) will be presented at the forthcoming 56th annual Society for Nuclear Medicine 2009 meeting (Toronto, Canada; 13-17 June). These antibodies target tumors expressing the cell surface proteins HER-2 and CD20, which are present on certain breast cancer and lymphoma cells, respectively. This is the first time that the targeted cancer cell-killing effect of 227Th-trastuzumab will be presented and suggests that further studies be conducted with this alpha-pharm...
Popular Cancer Drug Linked To Often Fatal Brain Virus
The 57-year-old lawyer in New York had handily completed the New York Times' Saturday crossword puzzle the hardest of the week for years. But one Saturday morning, suddenly he couldn't retrieve the words to fill in the squares. In Chicago, an 83-year-old woman began parroting the same phrases over and over. When her doctor asked her how she was, she replied, "I am fine. I am fine. I am fine." The symptoms of the New York lawyer and the Chicago woman could have been mistaken for early dementia. But an MRI brain scan and biopsy revealed something surprising. It looked like their brains had been eaten away. A brain biopsy and a spinal tap confirmed the diagnosis of a swiftly moving and often fatal viral brain infection called progressi...
Positive, Clinically Significant Phase III Results For Personalized Anti-Cancer Vaccine, Biovaxid, Presented At Asco Plenary Session-first Lymphoma Vaccine To Demonstrate Disease-Free Survival Benefit
TAMPA, Fla. -- --Compassionate-use program to soon launch in Europe Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. today announced that an eight year pivotal, randomized, multi-center, double-blind, controlled Phase III clinical study has shown that BiovaxID(R) (personalized therapeutic anti-cancer vaccine) significantly prolonged disease-free survival in follicular non-Hodgkin's lymphoma. The study, which is being featured at today's American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session, found that patients who received BiovaxID experienced a median disease-free survival of 44.2 months compared to 30.6 months for those who received a control vaccine -...
The Addition Of VELCADE For Injection To New And Standard Combinations Delivers Promising Results In Patients With Non-Hodgkin's Lymphoma
ORLANDO, Fla. -- Millennium: The Takeda Oncology Company today reported data from two clinical trials evaluating VELCADE(R) based combinations for patients with non-Hodgkin's lymphoma (NHL). The VERTICAL(1) Phase I/II trial evaluates a novel three-drug combination of VELCADE, rituximab and bendamustine (VcRB), which reported an 80 percent overall response rate (ORR) and 53 percent complete response (CR) rate in patients with relapsed or refractory follicular lymphoma (FL). The second study is a Phase I/II trial examining the use of VELCADE plus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VcR-CHOP) with modified vincristine dosing for patients with previously untreated indolent NHL. In this study,...
Cytokinetics Presents Clinical Data Relating To SB-743921 In Patients With Non-Hodgkin Or Hodgkin Lymphoma
SOUTH SAN FRANCISCO, CA -- Cytokinetics, Incorporated announced today that a poster presentation summarizing interim data from the Phase I portion of a Phase I/II clinical trial data evaluating SB-743921, a novel inhibitor of kinesin spindle protein (KSP), in patients with non-Hodgkin and Hodgkin lymphoma was presented at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) held from May 29 - June 2, 2009 in Orlando, FL. The poster highlighted that greater dose-density has been achieved with a dosing schedule of days 1 and 15 of a 28-day cycle in this clinical trial, as compared to a previous Phase I trial evaluating SB-743921. In addition, a potential amplified efficacy signal was observed without...
New Study Results Verify That PNH Cells Are Found In Majority Of Patients With Bone Marrow Failure Syndromes
CHESHIRE, Conn. -- Paroxysmal nocturnal hemoglobinuria (PNH) cells are present in the majority of patients with myelodysplastic syndromes (MDS), aplastic anemia (AA), and other bone marrow failure syndromes (BMF), according to interim results from 5,285 patients enrolled in the EXPLORE trial. EXPLORE (EXamination of PNH, by Level Of CD59 on REd and white blood cells) is the first large multicenter study to determine the frequency of PNH cells in these patient populations using a central laboratory conducting a high sensitivity test for PNH cells. The findings from EXPLORE will be presented tomorrow at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO). The EXPLORE trial was sponsored by Alexion P...
Two Targeted Therapies Likely Better Than One In Patients With Aggressive Lymphoma, Researchers Say
When combined with a cocktail of chemotherapy drugs, two monoclonal antibodies, instead of one, appear to offer superior results in patients with diffuse large B-cell lymphoma, according to Mayo Clinic researchers working with the North Central Cancer Treatment Group (NCCTG). At the annual meeting of the American Society of Clinical Oncology (ASCO), researchers say that adding the targeted therapy epratuzumab to a regimen known as R-CHOP resulted in an overall 12-month survival of 88 percent in 78 patients. While they call that a very good outcome, the researchers were especially encouraged because the survival rate was 85 percent in patients with high-risk disease. "These results are very good and very promising, and hopefully will b...
New Therapies To Treat Breast, Lymph Cancer: Studies
New therapies developed following groundbreaking clinical trials appear to effectively target breast cancer and non-Hodgkin's lymphoma, according to research unveiled Sunday at a major cancer conference. The first therapy targeting the capacity of cancer cells to repair themselves shows promise in treating breast cancer, according to results of two small clinical trials. The new agent, especially adept at targeting cancers that are most difficult to cure, neutralizes an enzyme called PARP (poly-ADP-ribose-polymerase) and prevents it from playing its usual role in repairing the DNA of damaged cells. Like healthy cells, cancerous cells employ PARP to regenerate themselves after they have been damaged by chemo-therapy treatments. T...







For more news about Non-Hodgkin Lymphoma go to MedWorm: Non-Hodgkin Lymphoma. This MedWorm page is more technical and is most likely more useful to oncologists. But for patients who want to know about cutting edge treatments and research for NHL, this MedWorm page will also be useful.

Powered by FirstRSS Plugin